Loopbaan van Nicolas Koebel
Eerdere bekende functies van Nicolas Koebel
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Oprichter | 01-10-2015 | 01-08-2022 |
| Corporate Officer/Principal | 01-10-2015 | 01-08-2022 | |
| ORCHARD THERAPEUTICS PLC | Oprichter | 01-08-2018 | - |
| Corporate Officer/Principal | 01-08-2018 | - |
Opleiding van Nicolas Koebel
| Institut D'études Politiques De Strasbourg | Graduate Degree |
| Institut de hautes études internationales et du développement | Undergraduate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 3 |
| Frankrijk | 2 |
| Zwitserland | 2 |
Operationeel
| Founder | 2 |
| Corporate Officer/Principal | 2 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Nicolas Koebel
- Ervaring
